Department of Bioengineering, University of Washington, Seattle, Washington 98195, United States.
Altis Biosystems, Inc., Durham, North Carolina 27709, United States.
Anal Chem. 2022 Jul 5;94(26):9345-9354. doi: 10.1021/acs.analchem.2c00905. Epub 2022 Jun 23.
Intestine is a common site of adverse drug effects in clinical trials; thus, improved models for preclinical screening of pharmaceutical compounds are sought. A planar, self-renewing human intestinal monolayer platform based on primary adult gastrointestinal stem cells, termed the 2D crypt model, has been developed to screen for the effects of various compounds on the intestinal epithelium. The 2D crypt platform is based on a standard 12-well plate format and consists of cell culture inserts with a collagen film overlaying an impermeable film patterned with an array of micron-scale holes. This two-chamber format enables a gradient of growth factors to be applied such that the tissue self-organizes into spatially segregated stem and differentiated cell compartments. The patterned monolayer mimics a gut epithelium in possessing a stem cell niche, migrating proliferative and differentiated cells. Once established, the 2D crypts replicate many aspects of physiology, including cell migration, maturation, and apoptotic cell death. The planar geometry of the system simplifies dosing, sampling, and imaging during assay. An immunofluorescence-based assay was established to quantitatively assess cell density, proliferation, migration, viability, and the abundance and localization of postmitotic lineages as a function of time. The model was used to perform a small-scale screen of compounds, including signaling molecules, endogenous hormones/cytokines, and microbial metabolites, on tissue homeostasis. Hit compounds that significantly impacted proliferation and/or differentiation were readily identified. The 2D crypt platform represents a significant innovation in the development of microphysiological systems for emulating the gut epithelium for compound screens.
肠道是临床试验中药物不良反应的常见部位;因此,人们正在寻找用于药物化合物临床前筛选的改进模型。基于成人胃肠道干细胞的平面、自我更新的人类肠道单层平台,称为 2D 隐窝模型,已被开发用于筛选各种化合物对肠道上皮的影响。2D 隐窝平台基于标准的 12 孔板格式,由带有胶原膜的细胞培养插入物组成,胶原膜覆盖着不可渗透的膜,该膜上有一系列微米级孔的图案。这种双室格式可以应用生长因子梯度,使组织自行组织成空间分离的干细胞和分化细胞区室。图案化的单层类似于具有干细胞龛、迁移增殖和分化细胞的肠上皮,具有许多生理特征。一旦建立,2D 隐窝复制了许多生理特征,包括细胞迁移、成熟和凋亡细胞死亡。该系统的平面几何形状简化了测定过程中的给药、采样和成像。建立了一种基于免疫荧光的测定法,以定量评估细胞密度、增殖、迁移、活力以及有丝分裂后谱系的丰度和定位随时间的变化。该模型用于对包括信号分子、内源性激素/细胞因子和微生物代谢物在内的化合物对组织平衡的小范围筛选。容易识别出对增殖和/或分化有显著影响的命中化合物。2D 隐窝平台代表了用于模拟肠道上皮进行化合物筛选的微生理系统开发的重大创新。